The treatment for CML was revolutionized by the development of BCR-ABL tyrosine kinase inhibitors (TKIs) which led to a markedly superior outcome compared to prior therapeutic options [2]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.